<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1521">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01944800</url>
  </required_header>
  <id_info>
    <org_study_id>GE IDE 00113</org_study_id>
    <secondary_id>2013-002272-40</secondary_id>
    <nct_id>NCT01944800</nct_id>
  </id_info>
  <brief_title>Prospective, Randomized Trial of Ticagrelor Versus Prasugrel in Patients With Acute Coronary Syndrome</brief_title>
  <acronym>ISAR-REACT 5</acronym>
  <official_title>Prospective, Randomized Trial of Ticagrelor Versus Prasugrel in Patients With Acute Coronary Syndrome - Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment (ISAR-REACT) 5</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Deutsches Herzzentrum Muenchen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Deutsches Herzzentrum Muenchen</source>
  <oversight_info>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Aim of the randomized, open-label, multicenter ISAR-REACT 5 trial is to assess whether
      ticagrelor is superior to prasugrel in patients with acute coronary syndrome and planned
      invasive strategy in terms of clinical outcomes.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Anticipated">October 2018</completion_date>
  <primary_completion_date type="Anticipated">October 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Composite of death, myocardial infarction or stroke</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bleeding</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Bleeding according to BARC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Death for any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stroke</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Stroke</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial Infarction</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent Thrombosis</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Stent thrombosis according to ARC</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">4000</enrollment>
  <condition>Acute Coronary Syndrome (ACS)</condition>
  <arm_group>
    <arm_group_label>Ticagrelor</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Prasugrel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ticagrelor</intervention_name>
    <description>Loading dose of 180 mg, followed by maintenance dose of 180 mg per day</description>
    <arm_group_label>Ticagrelor</arm_group_label>
    <other_name>Brilique</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prasugrel</intervention_name>
    <description>Loading dose of 60 mg, followed by maintenance dose of 10 mg/day or 5 mg/day in patients =/&gt; 75 years or &lt; 60 kg</description>
    <arm_group_label>Prasugrel</arm_group_label>
    <other_name>Efient</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Major Inclusion Criteria:

        Hospitalization for an acute coronary syndrome (ST-segment elevation myocardial
        infarction, non-ST-segment elevation myocardial infarction or unstable angina pectoris)
        with planned invasive strategy

        Major Exclusion Criteria:

          1. intolerance of or allergy to ticagrelor or prasugrel

          2. history of any stroke or transient ischemic attack

          3. intracranial neoplasm, intracranial arteriovenous malformation or intracranial
             aneurysm

          4. active bleeding, clinical findings, that in the judgement of the investigator are
             associated with an increased risk of bleeding

          5. fibrin-specific fibrinolytic therapy less than 24 h before randomization,
             non-fibrin-specific fibrinolytic therapy less than 48 h before randomization

          6. platelet count &lt; 100.000/μL at the time of screening

          7. anemia (hemoglobin &lt;10 g/dL) at the time of screening

          8. oral anticoagulation that cannot be safely discontinued for the duration of the study

          9. INR known to be greater than 1.5 at the time of screening

         10. chronic renal insufficiency requiring dialysis

         11. moderate or severe hepatic dysfunction (Child Pugh B or C)

         12. increased risk of bradycardia events (Sick Sinus, AV block grade II or III,
             bradycardia-induced syncope)

         13. index event is an acute complication (&lt; 30 days) of PCI

         14. concomitant medical illness that in the opinion of the investigator is associated
             with a life expectancy &lt; 1 year

         15. concomitant oral or i.v. therapy with strong CYP3A Inhibitors, CYP3A substrates with
             narrow therapeutic indices or strong CYP3A inducers that cannot be safely
             discontinued

         16. ≥1 doses of ticagrelor or prasugrel within 5 days before randomisation

         17. participation in another investigational drug study

         18. previous enrolment in this study

         19. pregnancy, giving birth within the last 90 days, or lactation

         20. inability to cooperate with protocol requirements
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adnan Kastrati, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Deutsches Herzzentrum München</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stefanie Schulz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Deutsches Herzzentrum München</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stefanie Schulz, MD</last_name>
    <phone>+49-89-1218-</phone>
    <phone_ext>0</phone_ext>
    <email>schulzS@dhm.mhn.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Barbara v. Merzljak</last_name>
    <phone>+49-89-1218</phone>
    <phone_ext>1534</phone_ext>
    <email>merzljak@dhm.mhn.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Florida, Health Science Center</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32209</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dominick Angiolillo, MD</last_name>
      <email>dominick.angiolillo@jax.ufl.edu</email>
    </contact>
    <investigator>
      <last_name>Dominick Angiolillo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitäts-Herzzentrum Freiburg/ Bad Krozingen</name>
      <address>
        <city>Bad Krozingen</city>
        <state>Baden-Württemberg</state>
        <zip>79189</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Franz-Josef Neumann, MD</last_name>
      <phone>+49 7633 402-2000</phone>
      <email>franz-josef.neumann@universitaets-herzzentrum.de</email>
    </contact>
    <contact_backup>
      <last_name>Barbara Steiger</last_name>
      <phone>+49 7633 402-5204</phone>
      <email>Barbara.Steiger@universitaets-herzzentrum.de</email>
    </contact_backup>
    <investigator>
      <last_name>Franz-Josef Neumann, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dietmar Trenk, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Schön Klinik Starnberger See</name>
      <address>
        <city>Berg</city>
        <state>Bavaria</state>
        <zip>82335</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jürgen Pache, MD</last_name>
      <phone>+49 8151 17-0</phone>
    </contact>
    <contact_backup>
      <last_name>Lisa Abenthum, Assistence</last_name>
      <phone>+49 8151 17-801</phone>
      <email>LAbenthum@Schoen-Kliniken.de</email>
    </contact_backup>
    <investigator>
      <last_name>Jürgen Pache, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Katharina Hoppe, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum rechts der Isar, 1. Medizinische Klinik und Poliklinik</name>
      <address>
        <city>München</city>
        <state>Bavaria</state>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isabell Bernlochner, MD</last_name>
      <phone>+49 89 4140 2350</phone>
      <email>isabell.bernlochner@mri.tum.de</email>
    </contact>
    <investigator>
      <last_name>Karl-Ludwig Laugwitz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Isabell Bernlochner, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Deutsches Herzzentrum Munich</name>
      <address>
        <city>München</city>
        <state>Bavaria</state>
        <zip>80636</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefanie Schulz, MD</last_name>
      <phone>+49-89-1218</phone>
      <phone_ext>0</phone_ext>
      <email>schulzS@dhm.mhn.de</email>
    </contact>
    <contact_backup>
      <last_name>Barbara v. Merzljak</last_name>
      <phone>+49-89-1218</phone>
      <phone_ext>1534</phone_ext>
      <email>merzljak@dhm.mhn.de</email>
    </contact_backup>
    <investigator>
      <last_name>Stefanie Schulz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Katharina Mayer, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kerckhoff-Klinik GmbH, Abteilung für Kardiologie</name>
      <address>
        <city>Bad Nauheim</city>
        <state>Hessen</state>
        <zip>61231</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Helge Möllmann, MD</last_name>
      <phone>+49 6032 996-2202</phone>
      <email>h.moellmann@kerckhoff-klinik.de</email>
    </contact>
    <contact_backup>
      <last_name>Heike Wagner, Study Nurse</last_name>
      <phone>+49 6032 996-5813</phone>
      <email>h.wagner@kerckhoff-forschungs-gmbh.de</email>
    </contact_backup>
    <investigator>
      <last_name>Helge Möllmann, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christian Hamm, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Herzzentrum Wuppertal</name>
      <address>
        <city>Wuppertal</city>
        <state>Nordrhein-Westfalen</state>
        <zip>42117</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Melchior Seyfarth, MD</last_name>
      <phone>+49 202 896 57 10</phone>
      <email>melchior.seyfarth@helios-kliniken.de</email>
    </contact>
    <contact_backup>
      <last_name>Marc Vorpahl, MD</last_name>
      <phone>+49 202 896 57 96</phone>
      <email>marc.vorpahl@helios-kliniken.de</email>
    </contact_backup>
    <investigator>
      <last_name>Melchior Seyfarth, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Segeberger Kliniken GmbH</name>
      <address>
        <city>Bad Segeberg</city>
        <state>Schleswig-Holstein</state>
        <zip>23795</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gert Richardt, MD</last_name>
      <phone>+49 4551 802</phone>
      <email>gert.richardt@segebergerkliniken.de</email>
    </contact>
    <contact_backup>
      <last_name>Daniela Schürmann-Kuchenbrand, Study Nurse</last_name>
      <phone>+49 4551 802 9947</phone>
      <email>daniela.schuermann-kuchenbrandt@segebergerkliniken.de</email>
    </contact_backup>
    <investigator>
      <last_name>Gert Richardt, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ralph Ernst Tölg, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vivantes Auguste-Viktoria-Klinikum</name>
      <address>
        <city>Berlin</city>
        <zip>12157</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Helmut Schühlen, MD</last_name>
      <phone>+49 030 130 20 2104</phone>
      <email>helmut.schuehlen@vivantes.de</email>
    </contact>
    <investigator>
      <last_name>Helmut Schühlen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Careggi University Hospital, Invasive Cardiology Division</name>
      <address>
        <city>Firenze</city>
        <zip>50141</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>David Antoniucci, MD</last_name>
      <email>david.antoniucci@virgilio.it</email>
    </contact>
    <contact_backup>
      <last_name>Fabio Torrini, Assistant</last_name>
      <email>cardiologia1@aou-careggi.toscana.it</email>
    </contact_backup>
    <investigator>
      <last_name>David Antoniucci, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
    <country>Germany</country>
    <country>Italy</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>November 25, 2013</lastchanged_date>
  <firstreceived_date>September 13, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ticagrelor</keyword>
  <keyword>Prasugrel</keyword>
  <keyword>Acute coronary syndrome</keyword>
  <keyword>Percutaneous coronary intervention</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Acute Coronary Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Prasugrel</mesh_term>
    <mesh_term>Ticagrelor</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
